Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CT-011 · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| CT-011 | DRUG | The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months. |
| FOLFOX | DRUG | FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days. mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours). |
Top 20 of 52 competitors
CT-011 is an investigational small molecule being studied for the treatment of metastatic colorectal cancer and melanoma. It is in Phase 2 clinical development for these oncology indications.
CT-011 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE.
CT-011 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials for CT-011 have been completed.
CT-011 has been studied in two completed Phase 2 trials. One trial, NCT00890305, evaluated FOLFOX plus CT-011 versus FOLFOX alone in metastatic colorectal cancer with 171 participants. Another trial, NCT01435369, studied CT-011 in patients with metastatic melanoma with 103 participants.
CT-011 is described as a small molecule in one context, but a trial title refers to it as a monoclonal antibody. The available information does not reconcile these descriptions, so its exact modality remains unclear.